Skip to main content

Table 1 Selected characteristics at presentation in 21 heart failure patients and healthy donors

From: Multi-level transcriptome sequencing identifies COL1A1 as a candidate marker in human heart failure progression

Basic informationHeart failure patients
n (percentage of 21)
Healthy donorsp value
Age (years)34.6 ± 15.941.7 ± 4.00.07
Male (percentage)13 (61.9)9(100)0.07
NYHA functional class, n (percentage of 21)
 II2 (9.5)  
 III7 (33.3)  
 IV12 (57.1)  
Comorbidities
 Diabetes mellitus2 (9.5)  
 Smoking history5 (23.8)  
 Pulmonary hypertension5 (23.8)  
 Tricuspid regurgitation12 (57.1)  
 Mitral regurgitation17 (81.0)  
Ultrasonic cardiogram
 LVEF (%)27.6 ± 9.8  
 LA (mm)44.7 ± 4.8  
 IVS-thickness (mm)8.2 ± 1.1  
 LVEDD (mm)65.1 ± 16.6  
Arrhythmia history, n (percentage of 21)
 Atrial fibrillation4 (19.0)  
 Premature ventricular contraction6 (28.6)  
 Ventricular tachycardia4 (19.0)  
 Ventricular fibrillation1 (4.8)  
 CRBBB3 (14.3)  
Drug therapy, n (percentage of 21)
 ASA2 (9.5)  
 Amio4 (19.0)  
 β-Blocker15 (71.4)  
 Digoxin16 (76.2)  
 ACEI/ARB17 (81.0)  
 CCB3 (14.3)  
 Diuretic18 (85.7)